Heron Therapeutics Q3 2026 Results: Net Loss of $5.01M, Loss Narrows
Heron Therapeutics filed its 10-Q for the period ended September 30, 2026, reporting 190,273,587 shares of common stock outstanding. The filing highlights a pending Asset Sale to CorMedix and notes significant risks regarding the company's ability to continue as a going concern without additional funding.
- Key figure
- Net loss $5.01M